Kaigene
Bethesda, US · Founded 2021 · Delaware corporation · 1 known investors
Kaigene is a Maryland biotechnology company developing therapeutic antibodies and fusion proteins for rare autoimmune diseases.
Also known as Kaigene Inc. · Kaigene, Inc.
Founders & leadership
Investors · 1
Reported raises · per SEC filings
Form D private placements$1.4M disclosed across 1 round · 2022
▶$1.4MraisedMar 2022 · 3 investors · BiotechnologyRule 506(b)
- Minjae ShinExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1.4M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Kaigene, Inc. is a preclinical-stage biotechnology company working on therapeutic antibodies and fusion proteins aimed at unmet clinical needs in rare autoimmune diseases. Its stated focus is on treatments that address the underlying mechanisms of autoimmune disorders, with research themes including pathogenic antibody degrader (PDEG) approaches, FcRn inhibition and B-cell suppression.
The company is organized into three research departments: antibody discovery, antibody engineering, and bioanalysis. Its laboratory operations are based in the Bethesda/North Bethesda area of Maryland, with company records also citing a Rockville, Maryland location. As of the SciSure case study, Kaigene employed 13 people and was recruiting additional researchers; it uses a digital scientific management platform for electronic lab notebook recordkeeping, research data retrieval and laboratory inventory management, having previously relied on office software and paper lab notebooks.
Business model
Kaigene is described as a business-to-business biopharmaceutical operation, with keywords indicating biopharmaceutical licensing alongside revenue-share and services/consulting arrangements. Its assets are preclinical drug-discovery programs rather than marketed products.
Traction
The company reported a team of 13 employees during its adoption of a scientific management platform, and a secondary-market data profile lists an employee count of 15 as of March 2026.
Latest developments
A vendor case study documents Kaigene's transition from paper and office-software recordkeeping to a digital scientific management platform for experiment documentation, data retrieval and lab inventory, with plans to continue using it for raw-data storage as the company grows.
▸Full profile — market position, technology, go-to-market, geography
Market position
Kaigene is characterized as a startup, growth-stage biotech in the drug-discovery segment of healthcare and life sciences, operating in the rare autoimmune disease therapeutics field.
Technology
Kaigene's work centers on antibody discovery and antibody engineering supported by an in-house bioanalysis function. Reported technical themes include therapeutic antibodies and fusion proteins, a pathogenic antibody degrader (PDEG) concept, FcRn inhibition, and B-cell suppression, applied to rare autoimmune disease targets. Laboratory workflows are documented in an electronic lab notebook and inventory system used for experiment records, raw-data storage and sample tracking.
Go-to-market
As a preclinical antibody developer, Kaigene's programs are directed at patients with rare autoimmune diseases, with commercial engagement oriented toward biopharmaceutical partners and licensees.
Geography
Operations are in Maryland, United States, with addresses reported at 12358 Parklawn Drive, Bethesda/North Bethesda, and a Rockville, Maryland headquarters listing.
Compiled by commissioned research from 3 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 3
by search overlap
Companies competing with Kaigene for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 1
launches, deals, and filingsKaigene replaced parallel paper and office-software recordkeeping with the SciSure electronic lab notebook and inventory platform to record experiments, retrieve research data and track laboratory materials.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structure▸Research sources · 3
primary sources listed
- Kaigene, Inc. - fund raising filingformds.com · web
3 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Kaigene do?
- Kaigene is a Maryland biotechnology company developing therapeutic antibodies and fusion proteins for rare autoimmune diseases.
- Who are Kaigene's investors?
- Kaigene's investors include Atinum Investment Co. Ltd..
- How much funding has Kaigene raised?
- Kaigene has disclosed $1.4M raised across 1 round.
- Where is Kaigene headquartered?
- Kaigene is headquartered in Bethesda, US.